3/22
10:51 am
glue
Monte Rosa Therapeutics (GLUE) Is a Great Choice for 'Trend' Investors, Here's Why [Yahoo! Finance]
Low
Report
Monte Rosa Therapeutics (GLUE) Is a Great Choice for 'Trend' Investors, Here's Why [Yahoo! Finance]
3/19
12:08 pm
glue
Wall Street Analysts Predict an 117.91% Upside in Monte Rosa Therapeutics (GLUE): Here's What You Should Know [Yahoo! Finance]
Low
Report
Wall Street Analysts Predict an 117.91% Upside in Monte Rosa Therapeutics (GLUE): Here's What You Should Know [Yahoo! Finance]
3/15
07:29 am
glue
Is Monte Rosa Therapeutics (NASDAQ:GLUE) In A Good Position To Invest In Growth? [Yahoo! Finance]
Medium
Report
Is Monte Rosa Therapeutics (NASDAQ:GLUE) In A Good Position To Invest In Growth? [Yahoo! Finance]
3/14
07:18 am
glue
Monte Rosa Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update [Yahoo! Finance]
Medium
Report
Monte Rosa Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update [Yahoo! Finance]
3/14
07:00 am
glue
Monte Rosa Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
Medium
Report
Monte Rosa Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
3/11
08:16 am
glue
MOMA Therapeutics Appoints Jullian G. Jones, Ph.D., J.D., MBA, as Chief Business Officer [Yahoo! Finance]
Medium
Report
MOMA Therapeutics Appoints Jullian G. Jones, Ph.D., J.D., MBA, as Chief Business Officer [Yahoo! Finance]
3/11
07:35 am
glue
Monte Rosa Therapeutics Announces Initiation of IND Enabling Studies for MRT-8102, A First-in-Class NEK7 Directed Molecular Glue Degrader and NLRP3/IL-1ß Pathway Inhibitor [Yahoo! Finance]
Medium
Report
Monte Rosa Therapeutics Announces Initiation of IND Enabling Studies for MRT-8102, A First-in-Class NEK7 Directed Molecular Glue Degrader and NLRP3/IL-1ß Pathway Inhibitor [Yahoo! Finance]
3/11
07:00 am
glue
Monte Rosa Therapeutics Announces Initiation of IND Enabling Studies for MRT-8102, A First-in-Class NEK7 Directed Molecular Glue Degrader and NLRP3/IL-1ß Pathway Inhibitor
Medium
Report
Monte Rosa Therapeutics Announces Initiation of IND Enabling Studies for MRT-8102, A First-in-Class NEK7 Directed Molecular Glue Degrader and NLRP3/IL-1ß Pathway Inhibitor
2/15
07:17 am
glue
Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE) is now covered by analysts at Wedbush. They set an "outperform" rating and a $11.00 price target on the stock.
High
Report
Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE) is now covered by analysts at Wedbush. They set an "outperform" rating and a $11.00 price target on the stock.
1/31
07:12 am
glue
Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences [Yahoo! Finance]
Low
Report
Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences [Yahoo! Finance]
1/31
07:00 am
glue
Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences
Low
Report
Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences
1/8
07:23 am
glue
Monte Rosa Therapeutics Provides Corporate Update and Key Anticipated Milestones for 2024 [Yahoo! Finance]
Medium
Report
Monte Rosa Therapeutics Provides Corporate Update and Key Anticipated Milestones for 2024 [Yahoo! Finance]
1/8
07:15 am
glue
Monte Rosa Therapeutics Provides Corporate Update and Key Anticipated Milestones for 2024
High
Report
Monte Rosa Therapeutics Provides Corporate Update and Key Anticipated Milestones for 2024
1/3
07:00 am
glue
Monte Rosa Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Low
Report
Monte Rosa Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference